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Activation of β2-adrenoceptors (β2ARs) causes airway smooth muscle (ASM) relaxation
and bronchodilation, and β2AR agonists (β-agonists) are front-line treatments for asthma
and other obstructive lung diseases. However, the therapeutic efficacy of β-agonists
is limited by agonist-induced β2AR desensitization and noncanonical β2AR signaling
involving β-arrestin that is shown to promote asthma pathophysiology. Accordingly,
we undertook the identification of an allosteric site on β2AR that could modulate the
activity of β-agonists to overcome these limitations. We employed the site identification
by ligand competitive saturation (SILCS) computational method to comprehensively
map the entire 3D structure of in silico-generated β2AR intermediate conformations and
identified a putative allosteric binding site. Subsequent database screening using SILCS
identified drug-like molecules with the potential to bind to the site. Experimental assays
in HEK293 cells (expressing recombinant wild-type human β2AR) and human ASM
cells (expressing endogenous β2AR) identified positive and negative allosteric modulators (PAMs and NAMs) of β2AR as assessed by regulation of β-agonist-stimulation of
cyclic AMP generation. PAMs/NAMs had no effect on β-agonist-induced recruitment
of β-arrestin to β2AR- or β-agonist-induced loss of cell surface expression in HEK293
cells expressing β2AR. Mutagenesis analysis of β2AR confirmed the SILCS identified
site based on mutants of amino acids R131, Y219, and F282. Finally, functional studies
revealed augmentation of β-agonist-induced relaxation of contracted human ASM cells
and bronchodilation of contracted airways. These findings identify a allosteric binding
site on the β2AR, whose activation selectively augments β-agonist-induced Gs signaling,
and increases relaxation of ASM cells, the principal therapeutic effect of β-agonists.

Significance
β2ARs are the primary targets for
relieving bronchoconstriction in
airway diseases such as asthma
and COPD. Activation of airway
smooth muscle (ASM) β2ARs
promotes therapeutic effects (via
β2AR-Gs pathway) that are
constrained by β2AR engagement
with the regulatory protein
β-arrestin. Moreover, chronic
activation of β2AR promotes
agonist-specific desensitization
that contributes to a loss of β2AR
function and the diminished
effectiveness of β-agonists in
managing asthma. Using
computational approaches, we
identified an allosteric site on an
intermediate conformation of
β2AR and associated positive
modulators that augmented:
1) beneficial signaling mediated
via the canonical β2AR-Gs
pathway; 2) relaxation of ASM
cells; and 3) dilation of airways
ex vivo induced by β-agonists,
outcomes that promote
therapeutic effects of β-agonists
in obstructive lung diseases.

adrenergic receptor | allosteric modulator | biased signaling | SILCS | asthma

Obstructive lung diseases such as asthma and chronic obstructive pulmonary disease are
characterized by increased bronchoconstriction and difficulty in breathing (1). Augmented
airway smooth muscle (ASM) contraction contributes significantly to the narrowing of
the airway lumen and various G protein-coupled receptors (GPCRs) expressed on the cell
surface of ASM regulate contraction or relaxation of ASM, and thus airway patency.
Activation of β2-adrenoceptors (β2AR) on ASM by endogenous (epinephrine and norepinephrine) and exogenous agonists promotes ASM relaxation and bronchodilation. Thus,
synthetic agonists of the β2AR (β-agonists) have been the principal therapeutic means of
relief of acute bronchoconstriction for decades. However, chronic β-agonist use has multiple deleterious effects, including worsening asthma control associated with increased
airway hyperresponsiveness and a loss of bronchoprotective effect as well as increased
mucus production and indices of airway inflammation (2–5). Of particular note, the
findings from the Salmeterol Multi-center Asthma Research Trial (SMART) study raised
mortality concerns that ultimately led to a black box warning for long-acting β-agonists
and more stringent guidelines for their clinical use (6). These studies underscore the need
for drug development strategies for β2AR ligands/modulators to effectively promote beneficial therapeutic effects while minimizing the deleterious effects of β-agonists.
β-agonists bind to β2AR at the orthosteric site of the receptor and promote the interaction of the β2AR with multiple signaling protein assemblies, including those of
Gs-protein, G protein receptor kinases, and β-arrestins (7). These signaling proteins are
capable of promoting multiple downstream signaling pathways resulting in ASM relaxation, negative feedback regulation (desensitization, receptor internalization), gene expression, and regulation of cell proliferation (8). Numerous cell, tissue, and in vivo studies
have attributed the therapeutic effects of β-agonists in asthma to canonical Gs signaling
by the β2AR, while the regulatory effects of β-arrestins constrain such therapeutic efficacy
(9–12) by promoting ASM β2AR desensitization, and reducing canonical Gs-cAMP-PKA
signaling and the prorelaxant effect of β-agonists on ASM (9, 12). More recent studies
have implicated β-arrestins in β-agonist-induced proinflammatory and pathogenic effects
in murine models of asthma (11, 13–18).
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Development of allosteric modulators of the β2AR, particularly
those capable of augmenting and biasing β2AR downstream signaling toward (therapeutic) signaling capabilities may overcome
the limitations of those β-agonists currently used to manage
asthma. Allosteric modulators bind to a receptor at sites distinct
from those bound by orthosteric ligands, to either augment (positive allosteric modulator (PAM)) or reduce (negative allosteric
modulator (NAM)) the signaling transduced by the orthosteric
ligand. Allosteric modulators (AMs) of GPCRs have potential
advantages over orthosteric ligands as therapeutic drugs. In the
absence of an orthosteric ligand, they lack activity and thus are
able to maintain activity dependence of physiological GPCR signaling (19, 20). Moreover, allosteric modulators offer the potential
of greater specificity of targeting, given the greater sequence diversity of allosteric modulator binding sites relative to those typically
engaged by orthosteric ligands (19, 20). To date, a few allosteric
modulators of β2AR have been identified, with their effects on
modulating signaling and arrestin recruitment characterized in
HEK293 cells expressing recombinant β2AR (21–23).
Experimental screening using DNA-encoded libraries identified
a β2AR NAM (21, 24) and a PAM (Cmpd 6) (22), with both
compounds having similar (negative and positive) modulation of
β-agonist-induced cAMP generation and arrestin recruitment. Liu
et al. identified a weak β2AR NAM using in silico docking, and
chemical optimization resulted in a balanced NAM for both Gs
activation and arrestin recruitment (22). Recent studies report
PAM Cmpd 6 acts as a positive modulator of the beta blocker
carvedilol, through enhanced binding affinity of carvedilol to
β2AR and enhanced β-arrestin binding (25). Cmpd 6 can also
increase the activity of carvedilol (but not of β1AR agonists) at the
β1AR and β1AR-arrestin-mediated signaling to confer cardioprotection (26).
In the present study to rationally identify additional allosteric
binding sites and small molecules capable of modulating signaling
by β2AR, we applied the site identification by ligand competitive
saturation (SILCS) approach (27, 28) using the program Climber
(29). The objective of this study was to target an intermediate
confirmation between the inactive and the ligand-bound active
state of β2AR. SILCS is a cosolvent molecular simulation approach
that maps the functional group affinity pattern of a protein,
including the protein interior, taking into account protein flexibility as well as protein and functional group desolvation contributions. Notably, the SILCS-Hotspots method allows for docking
a collection of fragments on the entire protein to identify putative
binding sites suitable for drug-like molecules (30). The SILCS
approach has previously been used to identify allosteric sites on
the proteins heme oxygenase (31) and β-Glucosidase A (32). In
addition, the SILCS-Pharmacophore (33) and Monte Carlo
(SILCS-MC) (34) methods are of utility for identifying drug-like
molecules that bind to the targeted sites, an approach we have
previously used to identify novel agonists of the β2AR (35).
Accordingly, in the present study, we apply the SILCS toolbox
and molecular dynamics (MD) simulations, to identify a previously unidentified allosteric site on β2AR along with putative AMs
that interact with the identified site, which were then subjected
to robust signaling and functional characterization. A detailed
description of the computational methods is given in the
SI Appendix.
Signaling studies of the SILCS-selected compounds identified
five positive (PAM) and three negative (NAM) allosteric modulators (AMs) of the β2AR based on their capacity to modulate
isoproterenol (ISO)-induced cAMP generation. Interestingly,
none of the AMs affected either ISO-induced β-arrestin recruitment to the β2AR or β2AR internalization. Computational and
2 of 12
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mutagenesis studies revealed the requirement of the β2AR amino
acids R131, Y219, and F282 for binding of the AMs. In addition,
the positive and negative allosteric modulators (PAMs and NAMs)
identified were able to modulate ISO-mediated relaxation of
human ASM cells and bronchodilation of airways in human and
murine precision-cut lung slices. This work describes the identification of an allosteric site on the β2AR and characterization of
β2AR AMs that bind to that site capable of selectively enhancing
canonical Gs signaling induced by β-agonists in human ASM cells
to improve the therapeutic function of the β2AR. Moreover, this
study provides a strategy for discovering AMs of β2AR that could
be applied to other GPCRs with therapeutic promise.
Results
Molecular Dynamics Simulations to Identify Intermediate
Conformational States. Molecular modeling and dynamics were

applied to identify conformations of the β2AR intermediate to
those of the active and inactive forms of the receptor. This was
performed using the protein structure morphing program Climber
which identifies conformations between two input conformations
(29). Starting from the active conformation, the structure was
gradually morphed leading to a decrease in the Climber energy
and the root-mean square difference (RMSD) with respect to
the inactive conformation. The RMSD increased with respect
to the active form (Fig. 1A). At the global minimum of the
Climber energy, reached at approximately morphing step 160,
the receptor attains the inactive conformation with respect to
the transmembrane (TM) helices with the subsequent increase
in Climber energy associated with the final morphing of loops
and side chain atoms. Two conformations, steps 74 and 143,
corresponding to energy minima along the morphing trajectory
with conformations intermediate to the active and inactive were
selected (Fig. 1A).
These two conformations were then subjected to a series of MD
simulations to comprehensively sample conformational space of
the receptor. The simulations were performed on the apo, agonist-bound, and inverse agonist-bound forms of both intermediates, with three individual simulations of each form performed
for each of the two intermediates. The ionic-lock distance between
residues R131 and E268 was used to define intermediate conformations with respect to the known inactive and active structures.
However, if the ionic-lock formed any salt bridge interactions
during the simulations, those simulations were not considered
further.
Analysis of the sampling of the β2AR conformations in the MD
simulations based on the ionic-lock distance is shown in Fig. 1
B–E. The results shown in Fig. 1 B–E are based on simulations
initiated from step 74, where the ionic lock is initially in an inactive-like conformation with an ionic-lock distance of 13.2 Å at
the beginning of the MD simulations, compared with the distance
of 11 Å present in the inactive 5X7D crystal structure. In the
simulation initiated with the agonist BI-167107, the distance is
steadily progressing toward a more active-like conformation with
an average distance of ~16 Å sampled toward the end of the simulation (Fig. 1B). In the simulation initiated with Carazolol, which
initially assumes an ionic-lock distance of ~14.5 Å, the system
undergoes a large shift in conformation at approximately 25-ns
(Fig. 1C) sampling ionic-lock distances around 18 Å, similar to
the distance of 19 Å observed in active-form crystal structure
3SN6. The associated conformations represent intermediate states
with the average ionic-lock distance intermediate to the experimentally observed distances from the crystal structures indicated
in Fig. 1 B and C. Subsequently, representative structures from
pnas.org
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Fig. 1. Molecular dynamics simulations identified intermediate conformational states. (A) Climber Energy (kcal/mol) (blue line) and RMSD with respect to inactive
(red dashed line) and active (red dash-dotted line) conformations (PDBIDs: 5X7D and 3SN6, respectively) during the morphing from the active to inactive form
of β2AR. Black dots display the local energy minima along the morphing pathway selected for the two starting intermediate conformations. (B–E) Ionic-lock
distance analysis from the MD simulations. (B and C) Time evolution of the ionic-lock distance from the MD simulations in the presence of BI-167107 or Carazolol,
respectively. Green vertical dashed lines represent the ionic-lock alpha carbon distance measured from the inactive (~11 Å) and active (~19.5 Å) receptor. (D and E)
Density distributions of the ionic-lock distance from the MD simulations in the presence of BI-167107 or Carazolol, respectively. The simulations in B and C
were initiated from the Step74 conformation.

the MD simulations were selected using RMSD clustering for
identifying conformations in which the ionic-lock distance corresponded to the average value from the MD simulations (Fig. 1
D and E). These structures were from simulations initiated from
Climber step 74 individually initiated with BI-167107 and
Carazolol, which will be referred to as Step74A and Step74B,
respectively.
SILCS Allosteric Binding Site Identification. Identification
of possible allosteric binding sites and subsequent database
screening to identify putative AMs were performed using SILCS
methodology (27, 28). SILCS simulations were performed to
generate functional group affinity maps (referred to as FragMaps)
for the intermediate β2AR conformations, Step74A and Step74B.
The SILCS method is based on Grand Canonical Monte Carlo
(GCMC) MD simulations using an explicit aqueous environment
that includes 8 solutes (35, 36). During the SILCS simulations,
water and solutes, representative of different functional groups,
compete around and throughout the entire protein, including
cryptic pockets that are deep or totally inaccessible to the
aqueous environment. Shown in Fig. 2A are the SILCS FragMaps
overlaid on the Step74A conformation used to initiate the SILCS
simulation. Evident are the apolar FragMaps around the TM region
of the protein that occupy regions adjacent to the hydrophobic
region of the bilayer, negative charged maps on the intracellular
face of the receptors, particularly around the ends of TM helices
5 and 6, and the presence of apolar, hydrogen bond donor and
acceptor, and positive FragMaps throughout the interior core of
the receptor. These latter maps indicate the utility of the SILCS
approach for identifying interior regions on the protein amenable
to the binding of various functional groups. Identification
of putative allosteric binding sites was done using the SILCSHotspots approach (30). This involved comprehensive docking
of 101 mono- and bicyclic chemical fragments in the field of the
FragMaps to generate fragment binding poses that encompass
the entire protein. Two rounds of clustering were then performed
from which final Hotspots that act as the basis for allosteric site
identification were identified. Shown in Fig. 2B are the Hotspots
on the Step74A conformer. The presence of Hotspots throughout
PNAS
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the protein, including the surface and interior regions, is evident,
consistent with the distribution of the FragMaps. Further in-depth
visual inspection of the Hotspots was then undertaken to identify
possible allosteric sites to which drug-like molecules would bind,
potentially acting as AMs.
Allosteric site selection focused on the identification of collections of adjacent Hotspots in which fragments occupying those
sites could potentially be linked to create drug-like molecules. In
this process, emphasis is on the relative location of adjacent
Hotspots and the presence of open regions between those hotspots
based on SILCS exclusion maps, with the rank ordering of the
Hotspots given lower priority, as described previously (30). In
addition, sites located in the vicinity of the residues known to
impact the activity of β2AR were given priority. From this process,
a site comprised of 3 Hotspots was identified. The site is present
in both the Step74A and Step74B systems between helices 3, 5,
6, and 7 (Fig. 2C and SI Appendix, Table S1). While analysis of
the solvent accessible surface in that region (Fig. 2D) shows minimal free space in the vicinity of those Hotspots as well as indicating the location of the binding site on the interior of the TM
bundle of helices, analysis of the SILCS exclusion maps around
the Hotspots (Fig. 2E) shows that the region between and around
the Hotspots is accessible for accommodating larger ligands. The
exclusion maps are defined based on the regions of the protein in
which the water or solutes do not sample during the SILCS simulations and, therefore, represent the extent to which the protein
can relax to allow ligand binding in contrast to a simple solvent
accessible surface based on a single protein structure. Accounting
for protein flexibility in the SILCS method clearly identifies
regions that can become accessible thereby facilitating the identification of putative binding sites not evident in single modeled or
experimental structures.
Allosteric Modulator Identification. In silico database screening
to identify putative AMs that bind to the identified site initially
involved screening using pharmacophores generated with the
SILCS-PHARM approach (33). This approach involves generation
of pharmacophore features in the vicinity of the selected Hotspots
based on the FragMaps in combination with clustering of the voxels
https://doi.org/10.1073/pnas.2214024119
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Fig. 2. SLICS approach identified an allosteric binding site on the β2AR. Structure of the Step74 conformation used to initiate the SILCS simulations (blue,
cartoon) along with (A) the SILCS FragMaps as mesh representations (apolar (green, −0.9), hydrogen bond donor (blue, −0.6) and acceptor (red, −0.6), negative
(orange, −1.2) and positive (cyan, −1.2 kcal), where the energy indicates the isocontour cutoff in kcal/mol), (B) SILCS-Hotspots throughout the entire protein
(VDW spheres, scaled by 0.7, colored by LGFE score from red to blue for the most favorable to least favorable ranked Hotspots ) and (C) 3 Hotspots selected that
define the identified allosteric site (red transparent oval) located below the orthosteric site (cyan transparent rectangle) between helices 3, 5, 6, and 7 (TM helix
numbers shown except 4, which is on the back of the image). (D and E) Step74 structure in the region of the allosteric binding site showing residues defining
the site (sticks, atom colored) and 3 selected Hotspots in the presence of the (D) Solvent Accessible Surface (white) or (E) SILCS Exclusion Map (tan). Compounds
shown in F, G, and H are the SILCS-docked orientations of positive or negative allosteric modulators (F) 36, (G) 37, and (H) 42 (CPK, atom colored) overlaid on the
side chains of the residues defining the allosteric binding site (stick, atom colored) and the pharmacophores used to select the respective compounds (VDW
spheres, hydrophobic (cyan), hydrogen bond acceptor (red), and hydrogen bond donor (blue)). The pharmacophores in panels G and H are identical. Residue
numbers in F are based on the Ballesteros nomenclature (PDB IDs shown in SI Appendix, Table S1).

that define the different FragMaps. From these pharmacophore
features, 8 pharmacophore hypotheses were selected for database
screening, with each containing 4 or 5 pharmacophore features.
Two example pharmacophores that ultimately identified
allosteric modulators are shown in Fig. 2 F–H, respectively, along
with the amino acid side chains lining the putative binding pocket
(labeled in Fig. 2F and SI Appendix, Table S1). The complementarity between the pharmacophore features and the adjacent amino
acids is evident. For example, the right side of 2F shows a hydrophobic feature (cyan sphere) surrounded by two Met, a Phe, and
a Leu residue. Interestingly, adjacent to R131 is a hydrogen bond
acceptor feature indicating that despite the positive charge of
R131, a negative functional group on a ligand in that region is
not highly favored.
Pharmacophore screening using Pharmer (37) produced up to
10,000 hits/pharmacophore based on RMSD of the ligand functional groups with respect to the pharmacophore features. The
selected compounds were then pooled and subjected to local optimization and scoring using SILCS–MC pose refinement from
which the Ligand Grid Free Energy (LGFE) scores were calculated.
From this step, the top 1,000 compounds were selected. These
compounds were then subjected to chemical fingerprint clustering
and bioavailability analysis using the 4D-Bioavailability metric
(38) from which a total of 100 chemically diverse compounds
were selected for purchase from the commercial vendor. All the
100 compounds were successfully obtained and subjected to biological evaluation yielding 8 lead compounds that modulated the
activation of β2AR (SI Appendix, Fig. S1). Of these, 5 where PAMs
and 3 were NAMs as described below. The predicted bound conformation of the 3 AMs subjected to comprehensive experimental
validation is included in Fig. 2 F–H.
4 of 12
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Lead Compounds Modulate Agonist-Induced cAMP Generation.

Activation of β2AR by orthosteric ligands leads to activation
of Gαs subunit, which in turn activates adenylyl cyclase (AC)
to hydrolyze ATP to produce cAMP (39). To determine the
biological activity of the AMs of the β2AR, HEK293 cells
overexpressing human wild-type β2AR were stimulated with
different concentrations of test compounds and evaluated
for cAMP production using a cAMP ELISA. None of the
compounds tested promoted cAMP accumulation in HEK293
cells (Fig. 3A). However, when cells were treated with varying
concentrations of test compounds along with 100 nM
isoproterenol (ISO), the PAMs and NAMs modulated ISOinduced cAMP generation in a dose-dependent manner (Fig.
3B). All subsequent studies were carried out using AMs at 100
nM based on these dose–response studies. Further, treatment
of HEK293 cells with ISO increased cellular cAMP levels in
a concentration-dependent manner (Fig. 3C). Costimulation
with ISO and 100 nM of different AMs significantly increased
or decreased the dose-dependent effect of ISO on cAMP
accumulation (Fig. 3C and SI Appendix, Fig. S3). Biological
evaluation of obtained compounds yielded 8 compounds that
modulated the activation of β2AR. Of these, compound 37
was the most effective PAM and compounds 36 and 42 were
the most effective NAMs (Fig. 3C and SI Appendix, Fig. S3).
These compounds were used in subsequent studies. EC50 and
Emax values of ISO alone or in combination with PAMs and
NAMs are depicted in Table 1.
To evaluate the observed modulating effects of PAMs and
NAMs on β2AR-Gs-cAMP signaling in a physiologically relevant
system, we further tested the effect of the compounds in primary
human ASM cells, which express β2AR endogenously. Concomitant
pnas.org
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Fig. 3. Effect of β2AR modulators on agonist-induced cAMP accumulation. Cells were plated into a 24-well plate and stimulated with vehicle or β2AR modulators
in combination with isoproterenol (ISO) for 10 min and cAMP accumulation was measured by ELISA as described in Methods. Isoproterenol (ISO)/ β2AR modulators
dose–response curve was generated using nonlinear (4-parameter) logistic curve from multiple experiments (n = 6). All statistical significances were determined
using a two-way ANOVA with Bonferroni post hoc analysis. (A) HEK293 cells expressing β2AR were stimulated with different concentrations of AMs or ISO. (B)
HEK293 cells expressing β2AR were stimulated with different concentrations of AMs and 100 nM ISO. Further, top ranking PAM and NAMs (100 nM) were used
to stimulate (C) HEK293 cells and (D) human ASM cells in combination with different concentrations of ISO. n = 5–8, *P < 0.05 (compound vs. ISO). (E) cAMP
generation was assessed in HEK293 cells expressing human β1AR stimulated with varying concentrations of ISO ± 100 nM AMs. n = 6. (F) Human ASM cells were
stimulated with different concentrations of prostaglandin E2 with vehicle or 100 nM AMs and cAMP was assessed. n = 5. Error bars represent ± SEM.

treatment of human ASM cells with PAMs or NAMs enhanced
or attenuated ISO-induced cAMP generation, respectively
(Fig. 3D and SI Appendix, Fig. S3). EC50 and Emax values of
ISO-induced cAMP generation in human ASM cells are given in
Table 1.
In order to establish the specificity of
the AMs to β2AR, we tested the effect of AMs on ISO-induced
cAMP generation in HEK293 cells expressing human β1AR. AMs
did not modulate ISO-induced cAMP generation in HEK293 cells
expressing β1AR (Fig. 3E). Further, in human ASM cells, which
express Gs-coupled EP2 and EP4 receptors, PAMs or NAMs did
not modulate prostaglandin E2-induced cAMP generation (Fig.
3F). Collectively, these findings suggest the specificity of the AMs
to β2AR.
AMs are Specific for β2AR.

Lead Compounds Do Not Affect β-Agonist-Induced Recruitment
of β-Arrestins. In addition to the canonical Gs signaling, the

“balanced” β-agonists induce β-arrestin recruitment to the
β2AR resulting in β2AR desensitization and activation of
noncanonical signaling such as ERK1/2 signaling (1). Therefore,
we aimed to determine the effect of compounds 37, 36, and
42 on ISO-induced β-arrestin2 recruitment to the β2AR using
a well-established bioluminescence resonance energy transfer
(BRET) assay (40). ISO treatment of HEK293 cells expressing
β2AR resulted in a dose-dependent increase in recruitment of
β-arrestin2 to the receptor (Fig. 4). Concomitant treatment of
cells with either PAM or NAMs did not alter ISO-mediated
changes in BRET (Fig. 4). Furthermore, we tested the effect
of AMs on ISO-induced phosphorylation of ERK1/2; neither
PAM nor NAMs altered ERK1/2 phosphorylation in HEK293
(Fig. 4B) or ASM cells (SI Appendix, Fig. S4). These data suggest
that increased β2AR-Gs signaling effected by the small molecule
PNAS
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PAM occurs without alterations in β-arrestin recruitment to the
β2AR, or noncanonical β-arrestin-dependent signaling induced
by orthosteric β-agonist.
AMs Do Not Modulate Binding of Orthosteric Agonist to β2AR.

PAMs or NAMs have the potential to influence β2AR signaling by
altering the affinity of the orthosteric ligand to β2AR. Therefore,
we tested the effect of AMs on the binding affinity of ISO to β2AR
using a well-established radiolabel ligand binding assay. AMs did
not alter binding affinity of ISO to the β2AR (Fig. 5 A–D).
Mutagenesis Studies Confirm the Mechanism of Action of Lead
Compounds. To validate the identity of the computationally

identified allosteric site, we generated β2AR containing R131K,
R131A, Y219F, Y219S, Y219A, F282Y, F282W, and F282A
mutations (Fig. 6A). Wild-type and mutant β2AR were expressed
in HEK293 cells, and ISO-induced cAMP generation was
measured in the presence or absence of the PAM compound 37,
or NAM compounds 36 and 42 (Fig. 6 B–E). The compounds
were also tested at different concentrations of ISO in the cells
expressing mutant β2AR (SI Appendix, Fig. S5). The cAMP
response was enhanced in cells expressing R131A and diminished
in F282A mutant β2AR compared with cells expressing wild-type
β2AR. The ISO-induced cAMP generation in cells expressing
wild-type and Y219A mutant β2AR was comparable (SI Appendix,
Fig. S5A). Further, as expected, compound 37 enhanced ISOinduced cAMP generation in cells expressing wild-type β2AR,
and this effect was abolished in cells expressing mutant β2AR
(Fig. 6 C–E and SI Appendix, Fig. S5 B–D). Furthermore, NAM
compounds 36 and 42 inhibited ISO-induced cAMP generation
in wild-type β2AR expressing cells, and this inhibition was
attenuated in cells expressing R131K, R131A, Y219F, Y219S,
Y219A, F282Y, F282W, and F282A mutant β2ARs (Fig. 6 C–E
https://doi.org/10.1073/pnas.2214024119
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Table 1. Effect of β2AR modulators on cAMP accumulation
Compound

EC50 [nM]

A. HEK293 Cells
18.76 ± 7.03
37

Emax [%]
normalized to veh

643.7 ± 36.25*

143.17 ± 5.63*

2

22.45 ± 9.04

432.96 ± 27.74

128.4 ± 13.64

31

105.69 ± 69.6

510.53 ± 68.64

113.55 ± 13.45

97.64 ± 63.23

577.3 ± 78.72

101.15 ± 8.01

84.4 ± 21.95

449.62 ± 22.31

100

410.95 ± 21.65

91.4 ± 5.27

4
Veh
39

15.58 ± 6.14

42

18.75 ± 30.99

374.64 ± 121.89

83.32 ± 32.53

6

50.09 ± 23.01

454.79 ± 36.42

77.87 ± 14.57

36

281.66 ± 108.3*

330.13 ± 33.48

73.42 ± 10.14

B. Human ASM cells
1139.29 ± 146.68
37
2
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Emax [pmol] raw
values

750.49 ± 168.88

633.85 ± 23.43*

178.93 ± 3.7*

448.43 ± 28.77

126.59 ± 6.42

4

524.25 ± 141.8

406.67 ± 29.16

114.8 ± 7.17

39

404.31 ± 115.82

400.63 ± 29.06

113.09 ± 7.25

Veh

618.66 ± 108.67

354.25 ± 16.72

100

6

307.54 ± 96.85

339.18 ± 24.63

95.75 ± 7.26

36

714.33 ± 235.5

238.42 ± 21.43*

31

120.52 ± 48.54

227.42 ± 16.74*

64.2 ± 7.36*

42

513.17 ± 275.92

130.25 ± 17.46*

36.77 ± 13.41*

67.3 ± 8.99*

EC50 and Emax for cAMP accumulation in (A) HEK293 and (B) human ASM cells stimulated
with different concentrations of ISO in the presence of vehicle or 100 nM AMs were calculated using non-linear regression curve on GraphPad Prism software. Values represent
mean ± SEM from n = 5–8.
*P < 0.05 (compound + ISO vs. Veh + ISO) using One-Way ANOVA with Dunnet post hoc
analysis.

and SI Appendix, Fig. S5 B–D). Collectively, these findings
demonstrate the critical requirement of amino acids R131,
Y219, and F282 of the β2AR in forming the binding pocket of
PAMs and NAMs.
Mutagenesis of the β2AR may influence the expression and
translocation of the β2AR to the cell surface. Therefore, to further
validate the mutagenesis experiments, we assessed the cell surface
expression of HA-tagged wild-type and mutant β2AR using cell
surface ELISA, as described previously (41). Baseline cell surface
expression of different mutants of the β2AR was similar to that of
wild-type β2AR (SI Appendix, Fig. S6).
Lead Compounds Do Not Alter β-Agonist-Induced Loss of
β2AR Cell Surface Expression. Previous studies have shown

that stimulation of β2AR with orthosteric ligands results in
concentration- and time-dependent loss of cell surface expression
of β2AR (42). Therefore, we next tested the effect of the PAM or
NAMs on the β-agonist-mediated loss of cell surface expression
of the β2AR. Treatment of HEK293 cells with ISO (100 nM)
for 15 min resulted in a loss of cell surface expression of the
β2AR (SI Appendix, Fig S6B). Treatment of cells with PAM 37 or
NAMs 36 and 42 in combination with ISO did not affect the ISOinduced loss of cell surface expression of wild-type or mutant β2AR
(SI Appendix, Fig S6B).
Lead Compounds Augment β-Agonist-Induced ASM Relaxation.

β-agonists are the drug of choice for the management of acute
bronchoconstriction in asthmatics, acting on the target ASM
cells. The Gs-cAMP-protein kinase A signaling axis effected
by β-agonists inhibits contraction of ASM cells via multiple
mechanisms (1, 43). We therefore examined whether the
modulation of this signaling pathway by the discovered PAM/
NAMs translated into functional differences in β2AR control
of ASM contraction. In a standard gel-contraction assay, the
6 of 12
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collagen gels containing human ASM cells were incubated with
different concentrations of ISO with vehicle or 100 nM AMs for
10 min, followed by stimulation with 10 μM histamine. The gel
images were obtained before and after treatment with different
agonists using an EVOS microscope, and a change in the gel
area was calculated. Treatment with 10 μM histamine decreased
the area of the gels, consistent with contraction of ASM cells.
Pretreatment of gels with ISO inhibited the histamine-induced
decrease in gel area (Fig. 7A). Pretreatment of gels with ISO in
combination with compound 37 significantly enhanced, whereas
compounds 36 and 42 either slightly reduced or had no effect,
on ISO-mediated inhibition of histamine-induced contraction
of human ASM cells (Fig. 7A).
To further examine the effect of PAMs and NAMs on β-agonistsmediated regulation of bronchorelaxation in a physiologically
relevant model, we used human and murine precision-cut lung
slices. Treatment of lung slices with the contractile agent methacholine resulted in the narrowing of airways. Lung slices were
treated with increasing concentrations of ISO plus either vehicle
or 100 nM of compounds 37, 36, or 42, and a change in airway
lumen area was determined. Treatment with ISO alone resulted
in a dose-dependent increase in airway lumen area (bronchodilation). This effect was significantly enhanced in the presence of 100
nM compound 37 and mitigated in the presence of compounds
36 and 42 (Fig. 7 B and C and SI Appendix, Fig. S7); the other
AMs tested had varying effects of ISO-induced bronchodilation
in murine lung slices (SI Appendix, Fig. S7). The EC50 and Emax
values for ISO-mediated relaxation of murine and human lung
slices are presented in Table 2.
Collectively, these results from cell- and tissue- based models
of ASM contraction strongly suggest that PAM properties of compound 37 extend to β2AR-Gs function (bronchodilation), with
the potential to be exploited therapeutically.
Discussion
Presented is a combined computational and experimental study
to identify allosteric modulators of the β2AR, which offer the
potential of improved therapeutic efficacy in the management of
obstructive lung diseases such as asthma. We utilized the computational SILCS approach to identify previously unidentified putative ligand-binding sites that would potentially act as allosteric
sites. To facilitate the identification of such sites, intermediate
conformations of β2AR, with respect to the active and inactive
conformations of the protein, were generated using the program
Climber followed by MD simulations of the receptor in its apo
form or in complex with BI-167107 or Carazolol. SILCS-Hotspots
analysis on the selected conformations identified a putative
allosteric binding pocket on the interior of the receptor, adjacent
to the ionic lock, suitable for the binding of drug-like molecules.
Subsequently, a combination of SILCS-Pharmacophore, Pharmer
and SILCS–MC pose refinement programs was used to identify a
collection of chemically diverse, commercially available compounds with suitable physiochemical properties as required for
experimental studies. From this list, a total of 100 compounds
were obtained and subjected to experimental evaluation. Among
these, eight compounds modulated β-agonist-induced cAMP generation in HEK293 cells expressing β2AR with no effect on the
recruitment of β-arrestins to the β2AR. In primary human ASM
cells expressing endogenous β2AR, the lead compounds enhanced
β2AR-mediated Gs signaling as measured by ISO-induced cAMP
generation. Importantly, a lead PAM 37 enhanced ISO-induced
relaxation of human ASM cells and bronchodilation of human
and murine airways ex vivo. Our study demonstrates that PAM
pnas.org
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Fig. 4. Effect of β2AR modulators on isoproterenol-induced β-arrestin recruitment and phosphorylation of ERK1/2. (A) Cells expressing BRET reporters (Rlucβ2AR and GFP-β-arrestin2) were treated with vehicle or 100 nM AMs with increasing concentrations of ISO and change in fluorescence was measured using
a plate reader. ISO treatment enhanced recruitment of β-arrestin to the receptor, and cotreatment of cells with AMs did not increase isoproterenol-induced
β-arrestin recruitment to the β2AR (n = 5). Error bars represent ± SEM. Graphpad Prism was used to generate nonlinear regression curves (4-PL) and a two-way
ANOVA with Bonferroni post hoc was used for statistical analysis. (B) ISO-induced activation of β-arrestin-ERK1/2 was assessed by western blotting and (C) band
intensities were normalized to β-actin. Data are expressed as fold change from vehicle-treated cells. AMs (100 nM) did not further modulate 100 nM ISO-induced
phosphorylation of ERK in HEK293 cells. n = 4 *P < 0.05 ISO vs. AMs + ISO using Student’s t test. Error bars represent ± SEM (B and C).

compound 37 selectively augments canonical β2AR-Gs-cAMP
signaling that translates into superior β-agonist-mediated bronchorelaxation. AMs do not directly modulate the binding affinity
of the orthosteric β-agonist to the receptor. Alternately, the AMs

might function by stabilizing the intermediate β2AR confirmations
thus keeping the receptor active for longer. Their interactions with
an intermediate conformation may also explain their lack of impact
on the affinity of the orthosteric β-agonist ISO.

Fig. 5. Effect of AMs on the binding affinity of ISO to the β2AR. Cell membranes expressing the β2AR were incubated with 3 nM [3H]DHA and with increasing
concentrations of ISO in the presence or absence of AMs. Nonspecific binding was assessed with 10 μM alprenolol. Binding competition curves were generated
using the function log(inhibitor) vs. response (three parameters) of the nonlinear regression curve fitting in GraphPad Prism and are represented as percentage
of the maximal [3H]DHA-specific binding. (A) Compounds 37, 36, and 42 were tested at 100 nM concentration and (B–D) subsequently, each of the compounds
was tested at different concentrations. n = 4. Error bars represent ± SEM.
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Fig. 6. Identification of the allosteric modulator binding site on the β2AR. Amino acids forming the putative binding pocket for the AMs on β2AR identified by
SLICS computational modeling are shown in (A). Wild-Type (WT) and mutant β2AR were expressed in HEK293 cells, and cAMP accumulation was measured upon
stimulation with 1 μM ISO (B). Cells were costimulated with vehicle or β2AR modulators (100 nM) and ISO (1 μM) for 10 min, and cAMP accumulation was measured
in cells expressing wild-type and Y219 (C), R131 (D), and F282 (E) mutant β2AR (n = 3–4, *P < 0.05 Compound + ISO vs. Veh + ISO, #P < 0.05 WT vs. β2AR mutant).
Student’s t test was used to determine statistical significances. Error bars represent ± SEM.

Computational Approach to Allosteric Binding Site Identification.

SILCS is a cosolvent molecular simulation approach that maps
the functional group affinity pattern of a protein, including the
protein interior, taking into account protein flexibility as well as
protein and functional group desolvation contributions. Notably,
the SILCS-Hotspots method allows for docking a collection of
fragments on the entire protein to identify putative binding sites
suitable for drug-like molecules (30) in a highly computational
efficient fashion with a level of accuracy comparable with other
state-of-the-art computational methods such as free energy
perturbation (44). The present results further represent the
capability of the SILCS method to identify allosteric binding sites
showing, notably, its utility against a GPCR (30, 32, 35). The
technology takes advantage of the inclusion of protein flexibility
in SILCS combined with the use of GCMC water and solute
sampling to identify possible binding sites on the interior of a
protein not evident in experimental crystallographic or cryo-EM
structures. Further improvements in the SILCS approach may
include enhancement of the conformational sampling of the
protein, possibly through increasing the simulation temperature,
as well as generating additional intermediate conformations of
the GPCR. The latter could be achieved through a number of
enhanced sampling simulation technologies (45).
Our study identified a previously unidentified allosteric site on
the β2AR comprised of amino acids R131, Y219, and F282. The
SILCS-Hotspots-identified allosteric binding site (Fig. 2 B and
C) is located roughly 20 Å below the orthosteric binding site inside
the TM bundle. The Hotspots that make up the site were of interest as they are located just below the PIF connector motif (P211,
I121, and F282) (46) and extend out toward the core of the TM
bundle. This central site is completely inaccessible in the inactive
8 of 12
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conformation as it is occupied by TM helix 6. However, in the
intermediate conformation identified using Climber and in the
conformations sampled during the subsequent MD simulations,
R131 shifts up toward the site previously occupied by helix 6 that
has been observed in an experimental structure of the activated
receptor (47). Further, our findings suggest that mutation of R131
enhances ISO-induced cAMP accumulation (SI Appendix, Fig.
S5A) consistent with the previously published literature (48, 49).
Mutation in F282 on the contrary attenuated ISO-induced cAMP
generation similar to what has been shown previously (48). The
cAMP generation in cells expressing Y219A mutant receptor was
comparable with the wild-type receptor. Importantly, the AMs
did not have any effect on ISO-induced cAMP generation in cells
expressing mutant β2AR supporting our hypothesis that AMs
potentially bind to a pocket formed by these three amino acids
(Fig. 6 C, D and E and SI Appendix, Fig. S5 B, C and D). Further,
cell surface expression ELISA findings demonstrated that AMs do
not modulate ISO-induced internalization of the β2AR. A previous study demonstrated that mutation in Y219 renders the β2AR
resistant to agonist-induced desensitization and internalization
(50). However, we observed an ISO-induced loss of cell surface
expression with the Y219 mutant, mostly likely due to significant
differences in experimental approach including different cell systems, which are known to produce variable results in studies of
β2AR regulation (51).
Notably, the present site does not correspond to a previously
identified allosteric sites on β2AR. The first identified β2AR modulator, a NAM, binds to the intracellular termini of TM helices
1, 2, 6, and 7 (21). A PAM (Cmpd 6), binds to a pocket formed
by ICL2 and TM helices 3 and 4 (23) and more recently, a NAM
was identified and shown to bind to TM helices 3 and 5 (22).
pnas.org

Table 2.
Compound

Bronchodilation of precision cut lung slices
EC50 [nM]

A. Human PCLS
129.36 ± 54.84
37

Emax [%]
normalized to veh

68.86 ± 5.16*

143.64 ± 7.49*

Veh

266.89 ± 114.55

47.94 ± 4.51

100

36

355.97 ± 174.79

36.06 ± 4.78

75.23 ± 13.26

42

354.75 ± 175.99

16.9 ± 1.94*

B. Murine PCLS
551.88 ± 134.33
37

43.23 ± 1.91*

177.33 ± 4.42*

1128.57 ± 404.04

39.02 ± 3.05*

160.05 ± 7.82*

4

35.26 ± 11.47*

2

509.18 ± 198.49

37.84 ± 2.56*

155.23 ± 6.76*

6

231.51 ± 72.04

24.63 ± 1.16

101.03 ± 4.73

Veh

788.67 ± 328.16

24.38 ± 1.96

100

39

834.19 ± 391.81

24.11 ± 2.17

98.89 ± 9.02

174.56 ± 66.73

21.35 ± 1.12

87.58 ± 5.24

36

2203.36 ± 1827.42

13.56 ± 2.62*

55.62 ± 19.29*

42

749.99 ± 463.84

9.42 ± 1.47*

38.64 ± 15.63*

31
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Emax raw values

EC50 and Emax of ISO for bronchodilation of (A) human and (B) murine precision cut lung
slices in the presence of vehicle or AMs (100 nM) were calculated using nonlinear regression curve on GraphPad Prism software. Values represent mean ± SEM from n = 5–8.
*
P < 0.05 (compound+ISO vs. Veh+ISO) using One-Way ANOVA with Dunnet post hoc analysis.

Fig. 7. Effect of allosteric modulators on β-agonist-mediated inhibition of
contraction of human ASM cells and augmentation of bronchodilation in
human and murine lung slices. (A) Collagen gels containing human ASM cells
were pretreated with veh or AMs (100 nM) and different concentrations of
ISO for 10 min and stimulated with histamine (10 μM). Images of collagen
gels were taken at 10-min intervals over 30 min and normalized to the basal
area for each measure. Data are representative of n = 6–10 independent
donors. *P < 0.05 His vs. ISO + His, #P < 0.05 Veh + ISO vs. Compound + ISO.
His, histamine. (B) Human and (C) murine lung slices were contracted with
methacholine (1 μM) for 10 min and treated with vehicle or β2AR modulators
(100 nM) for 10 min followed by treatment with an increasing concentration of
ISO. Change in lumen area of airways was used to determine the magnitude
of bronchodilation. n = 8, *P < 0.05 Veh + ISO vs. Compounds + ISO. Nonlinear
curve fitting (Inhibitor vs. three-parameter for A and agonist vs. four-parameter
logistic curve fit for B and C) was generated using Graphpad Prism software. All
statistical differences were analyzed using a two-way ANOVA with Bonferroni
post hoc analysis. Error bars represent ± SEM.

Interestingly, these two allosteric sites (21, 22) are located on the
protein-membrane interface and may potentially modulate the
receptor response from the membrane side by impacting G-protein
binding or by disrupting the polar network around the activation
switch and thus stabilizing the inactive receptor conformation.
PNAS
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e2214024119

Concerning the activity of the present allosteric modulators, the
location of the site is below the orthosteric site in a deep pocket
in the central region of the TM helices (Fig. 2 D and E). Shown
in SI Appendix, Fig. S2 of the Supplement are bound orientations
of 36, 37, and 42 along with the SILCS FragMaps further demonstrating the compounds’ ability to participate in favorable interactions with the binding site. The similar orientations of the
compounds and location of the allosteric site along with the lack
of large changes in the EC50 values for ISO in the experiments
assessing cAMP generation (Fig. 3 and Table 1), indicates that the
mechanism of action would be to stabilize specific conformations
of the receptor rather than directly impacting the binding of agonists to the orthosteric site. This would involve a shift in the
conformations toward more or less active conformations based on
the details of the specific interactions of the compounds with the
region around the binding site given that both PAMs and NAMs
have been identified. In addition, these changes would impact G
protein interactions over those with β-arrestin based on the arrestin recruitment experiments (Fig. 4). Further, our radioligand
binding data suggest that AMs do not modulate orthosteric ligand
binding affinity on β2AR (Fig. 5) unlike other β2AR allosteric
modulators that have been described in the literature, probably
because the AMs identified in our study bind to an intermediate
conformation as opposed to a fully activated conformation of
β2AR to which the other known allosteric modulators bind.
However, further details of the mechanism will require detailed
structural and computational biology analyses.
Biological Effects of PAM and NAM and Clinical Significance. It is

well-appreciated that the therapeutic efficacy of β-agonists involves
complex interplay of interaction between the β2AR and G proteins,
kinases, and β-arrestins (7–9). GRKs and β-arrestins are key
regulatory molecules involved in agonist-specific desensitization
of numerous GPCRs, limiting the capacity of receptor to maintain
signaling, and the associated functional consequences. β-agonists
are used as both prophylaxis and treatment for asthma, based
on their ability to reverse bronchoconstriction caused by ASM
contraction. Yet chronic β-agonist use by asthmatics is associated
with a loss of drug efficacy, including a loss of bronchoprotective
effect, and worsening of asthma control (2, 5, 52, 53). Studies
https://doi.org/10.1073/pnas.2214024119
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using ASM cells and murine models of asthma, strongly implicate
GRK- and β-arrestin- mediated β2AR desensitization in the loss
of bronchoprotection by β-agonists, as molecular and genetic
strategies targeting these regulatory molecules augment and sustain
β2AR-stimulated cAMP and PKA signaling, while increasing
β2AR-agonist-mediated ASM relaxation and bronchorelaxation
(9, 10). In addition, numerous recent studies have also implicated
β-arrestin2 in promoting β2AR-dependent development of the
asthma phenotype in murine models of asthma presumably via
noncanonical β2AR signaling that occurs via the formation of
a β-arrestin2 scaffold (11, 54). Thus, identification of agents
that help overcome the constraints imposed by GRKs/arrestins
represents exciting therapeutic candidates.
Augmenting Gs-cAMP signaling by β2AR would potentially
provide therapeutic benefit. In this regard, to a limited extent,
phosphodiesterase inhibitors can augment canonical β2AR-cAMP
signaling. Yet their use in asthma appears to have limited efficacy
and is complicated by significant off-target effects (54, 55). PAMs
provide an alternative means of augmenting β2AR-cAMP signaling. While one other β2AR PAM has been reported to date, its
characterization has been largely limited to signaling studies of
HEK293 cells (22, 25, 26). In this study, we identified PAMs that
increase cAMP signaling transduced by ISO in human ASM cells.
Considering the endogenous level of β2AR expression in human
ASM the modulatory effects of AMs are different in ASM cells
compared with that observed in the HEK293 cells. Consistent
with our previous studies establishing the functional consequences
of increasing ASM β2AR-cAMP signaling, compound 37 significantly increased the ISO-induced relaxation of contracted human
ASM cells and human and murine airways. Our study provides a
proof-of-concept that ligands binding to a unique allosteric site
on the β2AR, can modulate cAMP signaling in ASM cells. This
finding has wide-ranging implications given the prominent role
of canonical β2AR-Gs-cAMP in regulating cellular functions in
multiple organ systems.
Coinciding with the promotion of Gs-cAMP signaling, interaction of agonist-occupied β2AR with GRKs results in phosphorylation of the receptor and recruitment of arrestins followed by
desensitization of β2AR and activation of noncanonical signaling.
Given activation of arrestin-mediated signaling by β-agonists is
dose- and time-dependent, the ability of PAM to achieve a
Gs-mediated relaxation at a lower β-agonist concentration is desirable. For these reasons, molecules that bias β2AR signaling toward
Gs without affecting β-arrestin recruitment could potentially limit/
avoid problems demonstrated with use of balanced β-agonists.
In summary, our study identifies a allosteric binding site on the
β2AR activation of which selectively enhances canonical Gs-cAMP
signaling in both cell lines transduced with β2AR and physiologically relevant cells. Importantly, such signaling modulation translates into increased β2AR function in ASM cells and tissues,
rendering compound 37 and similar PAMs promising therapeutic
tools in the management of obstructive lung diseases.
Materials and Methods
Computational Methods. A detail description of the computational methods
is presented in the SI Appendix.

Compounds were purchased from
Chembridge (San Diego, CA). The compounds were procured at 5–25 mmol
quantity and dissolved in 10% DMSO to prepare 10 mM stock solutions.

Preparation of β2AR Modulators.

Cell Culture. HEK293 cells: HEK293 cell lines were obtained from the American

Type Culture Collection (ATCC) and maintained in Dulbecco's modified Eagle's
medium (DMEM) as described previously (41).
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Human ASM cells: Human ASM cells were isolated from deidentified donor
lungs and cultured using F-12 media supplemented with 10% FBS, penicillin and
streptomycin, HEPES buffer, CaCl2, L-Glutamine (Gibco, Waltham, MA), and NaOH
between 2 and 6 passages as described previously (56). Donor lungs were obtained
from National Disease Research Institute and use of cells and tissues from deidentified donors have been judged to be Not Human Subjects research by TJU IRB.
Transfection of HEK293 Cells. cDNA Constructs and Transfections: The human
β2AR cDNA containing 3-HA tag at N terminus subcloned into a pcDNA3.1 was
obtained from www.cdna.org. Binding site residues PHE(F)282, TYR(Y)219, and
ARG(R)131 were mutated to different amino acids using the QuikChange II XL
Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) per the manufacturer's
protocol. Mutations were confirmed by DNA sequencing. HEK293 cells were transfected with cDNA expressing (wild type or mutant; see below) human β2AR using
Lipofectamine 3000 (Invitrogen, Waltham, MA) and used for studies within 36–48
h, or were maintained in media containing G418 at 500 μg/ml concentration.
Expression of β2AR was confirmed by western blotting and confocal imaging
using an anti-HA antibody (41).
cAMP Assay. Cells were grown to full confluency in 24-well plates, serum-starved

for 24 h, and then incubated with 1 mM IBMX for 10 min. Cells were then incubated with ISO (1 nM to 10 μM) or β2AR modulators alone or concomitantly for
10 min and cAMP levels were measured by ELISA (Life Technologies, Waltham,
MA) as described previously (57, 58).
Arrestin Recruitment to the β2AR Assay (Bioluminescence Resonance
Energy Transfer; BRET). β-agonist-induced recruitment of β-arrestin to the

β2AR was assessed by BRET assay as described previously (40). HEK293 cells
were transfected with pcDNA-β-arrestin2-GFP10 and pcDNA3-β2AR-RlucII, and
after 48 h the cells were treated with increasing concentration of ISO and vehicle
or 100 nM PAMs or NAMs followed by the addition of Coelenterazine 400a for
20 min. Change in BRET was measured using a Tecan Infinite F500 microplate
reader. BRET ratios were calculated by dividing the intensity of light emitted by
the GFP10 acceptor by the total light emitted by the RLucII donor.

Radioligand Binding Assay. Competitive radioligand binding assay was per-

formed as previously described (59). Cells expressing β2AR were lysed and cell
membranes were incubated in 3 nM [3H]-dihydroalprenolol ([3H]DHA) with
increasing concentration of ISO ± AMs. Bound radioactivity was measured with
a TriCarb 4910 TR liquid scintillation analyzer (PerkinElmer, Waltham, MA) and
expressed as % of maximum [3H]DHA specific binding. Nonspecific binding was
assessed with 10 μM alprenolol. Binding competition curves were generated
using nonlinear regression curve fitting function log(inhibitor) vs. response (three
parameter) in GraphPad Prism and normalized to percentage of maximal [3H]
DHA specific binding.
Cells were lysed in RIPA buffer (Cell Signaling Technology,
Denvers, MA) containing protease and phosphatase inhibitors (Bimake, Houston,
TX) after treating with agonists for 10 min. Proteins were separated using SDSPAGE, transferred onto nitrocellulose membranes, and probed with primary antibodies phospho-ERK1/2 and β-actin. Secondary antibody (Li-Cor) was used to
quantify target protein using Odyssey scanner (Li-Cor, Lincoln, NE) and analyzed
using ImageStudio software (Li-Cor, Lincoln, NE) as described previously (41, 60).
Immunoassays.

Receptor Internalization. ISO induced receptor internalization was assessed via

cell surface ELISA as previously described (41, 60). Briefly, HEK-293 cells expressing
β2AR were plated on 24-well plates. Cells were treated with100 nM ISO with vehicle
or 100 nM AMs for 15 min. Post treatment, cells were washed and fixed with 10% formalin-buffered saline for 10 min on ice, washed twice, and further processed using
horseradish peroxidase-conjugated chicken polyclonal anti-HA antibody (Abcam).
Cells were washed and incubated with 3,3′,5,5′-tetramethylbenzidine substrate
and transferred to a 96-well plate containing sulfuric acid to stop the colorimetric
reaction. FlexStation3 was used to measure absorbance at 450 nm. All values were
normalized to basal value (no ISO/AMs) of wild-type receptor.
ASM Cell Contraction Using Collagen Gel. Onto a 96-well plate, 100 μl ASM
cell suspension (5 × 105 cells/ml) containing type-I rat tail collagen (1.5 mg/ml)
in F-12 medium was seeded (61). After 24 h, collagen gels were loosened from the
plate. The contraction was initiated by adding histamine (10 μM), with or without

pnas.org

pretreatment with increasing concentration of ISO, with vehicle or AMs for 10
min prior to histamine. Images were obtained using an EVOS live tissue microscope before and at 10-min intervals for 40 min after the addition of histamine.
Gel area was obtained for each of the mages using NIH ImageJ software. Data
were expressed as percentage gel contraction and calculated using the following
equation: [(T0 gel area - T10 gel area) / T0 gel area × 100%].
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Ex Vivo Airway Functional Studies Using Murine Precision-Cut Lung
Slices. FVB mice expressing human β2AR in smooth muscle were used in this

study (62). The protocol for animal experiments is approved by the Institutional
Animal Care and Use Committee at Thomas Jefferson University. Murine lungs
were perfused with 4% low-melting agarose, allowed to solidify at 4 for 1 h. For
human airways, a small lobe was inflated with 2% low melting point agarose
and cores of 8 mm in diameter were made. Both human and murine lungs
were then sliced (~250 μm thick) using an oscillating tissue slicer (OTS-5000,
FHC Inc). Lung slices cultured for 48 h were treated with methacholine (MCh,
1 μM), and images of the airways were obtained before and 10 min after MCh
stimulation using EVOS FL Auto (Life technologies, Waltham, MA) microscope
(63). The lung slices were treated with ISO (1 nM – 10 μ M) with vehicle or AMs,
and images of the airways were captured at 10-min intervals for a total of 50
min. Images of airways were used to calculate the area of airways using Image
J software (NIH). Data from lung slice experiments were plotted as a percentage
of methacholine-induced decrease in airway area compared with baseline area.
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